Amussen Hunsaker Associates LLC Pds Biotechnology Corp Transaction History

Amussen Hunsaker Associates LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $222,797 - $434,342	75,016 New	75,016 $223,000
Q3 2021 Nov 16, 2021	SELL	$9.33 - $17.08 $235,479 - $431,082	-25,239 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$4.35 - $12.86 $109,789 - $324,573	25,239 New	25,239 $316,000
Q1 2021 May 18, 2021	SELL	$2.28 - $6.81 $30,077 - $89,837	-13,192 Closed	0 $0
Q3 2020 Nov 23, 2020	BUY	$1.67 - $4.67 $22,030 - $61,606	13,192 New	13,192 $31,000
Q3 2020 Nov 16, 2020	SELL	$1.67 - $4.67 $22,030 - $61,606	-13,192 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$0.65 - $2.6 $8,574 - $34,299	13,192 New	13,192 $27,000
Q4 2019 Feb 14, 2020	SELL	$2.08 - $4.07 $30,453 - $59,588	-14,641 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$3.38 - $6.71 $49,486 - $98,241	14,641 New	14,641 $49,000

4.26M

163K

6.1K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $38.7M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Amussen Hunsaker Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Amussen Hunsaker Associates LLC with notifications on news.